Lord O’Shaughnessy to discuss his review into clinical trials
The House of Lords Science and Technology Committee will hold a one-off evidence session into the landscape for clinical trials in the UK.
The Committee will hear from Lord O’Shaughnessy, who recently published a review into the landscape for clinical trials in the UK. The review was published on May 25, 2023, alongside the Government’s response, and this in turn was announced alongside a package of funding for the life sciences.
The headline ambition recommended by the report is that the Government should “double the numbers of people taking part in commercial clinical trials by 2025, and double it again by 2027.”
The session will focus on the outcomes of this review, the recommendations made to Government to improve the landscape for clinical trials in the UK, and the factors behind the recent decline in health research in the NHS which has been highlighted by the Association of the British Pharmaceutical Industry and other bodies.
Meeting details
Possible question areas
- Why has the clinical trials environment in the UK worsened in recent years?
- How can the NHS ensure that research time is prioritised and protected for clinicians?
- What can we learn from the success of clinical trials during the COVID pandemic?
- What role do the regulators of clinical trials need to play in supporting the system?
- Is the Government’s response to the review adequate, and what should we watch for in the future?